Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (21272)	4/23/1999 4:56:00 PM
From: VLAD	Respond to of 23519

RT, You are IMO absolutely correct.

To: RT who wrote (21272)	4/23/1999 5:46:00 PM
From: DaiS	Read Replies (2) \| Respond to of 23519

RT, We know from the studies available that some men failing muse responded to alibra, but it is not clear how many men succeed on muse but not on alibra. It puzzles me the small amount of alprostadil in alibra.....I thought that Vivus might be sacrifing some efficacy to lower price and wider target population. But then I thought that this target population might overlap more with viagra target population than does muse? I take the point that a small market for muse might not make it commercially viable. I am confident that Vivus have got this one worked out - no I mean it. DaiS